NTLA
Price
$14.26
Change
-$0.86 (-5.69%)
Updated
Nov 15, 03:31 PM (EDT)
97 days until earnings call
SONN
Price
$3.09
Change
+$0.09 (+3.00%)
Updated
Nov 15, 03:18 PM (EDT)
Ad is loading...

NTLA vs SONN

Header iconNTLA vs SONN Comparison
Open Charts NTLA vs SONNBanner chart's image
Intellia Therapeutics
Price$14.26
Change-$0.86 (-5.69%)
Volume$475
CapitalizationN/A
Sonnet BioTherapeutics Holdings
Price$3.09
Change+$0.09 (+3.00%)
Volume$100
CapitalizationN/A
NTLA vs SONN Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
NTLA vs. SONN commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and SONN is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (NTLA: $15.12 vs. SONN: $3.00)
Brand notoriety: NTLA and SONN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 94% vs. SONN: 16%
Market capitalization -- NTLA: $1.54B vs. SONN: $2.05M
NTLA [@Biotechnology] is valued at $1.54B. SONN’s [@Biotechnology] market capitalization is $2.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $475.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 0 FA rating(s) are green whileSONN’s FA Score has 1 green FA rating(s).

  • NTLA’s FA Score: 0 green, 5 red.
  • SONN’s FA Score: 1 green, 4 red.
According to our system of comparison, both NTLA and SONN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while SONN’s TA Score has 2 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 4 bearish.
  • SONN’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than SONN.

Price Growth

NTLA (@Biotechnology) experienced а -5.50% price change this week, while SONN (@Biotechnology) price change was -18.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.07%. For the same industry, the average monthly price growth was +3.27%, and the average quarterly price growth was +5.23%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 20, 2025.

SONN is expected to report earnings on Nov 29, 2023.

Industries' Descriptions

@Biotechnology (-2.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.54B) has a higher market cap than SONN($2.05M). NTLA YTD gains are higher at: -50.410 vs. SONN (-78.448).
NTLASONNNTLA / SONN
Capitalization1.54B2.05M75,195%
EBITDAN/AN/A-
Gain YTD-50.410-78.44864%
P/E RatioN/A0.29-
RevenueN/AN/A-
Total CashN/A3.55M-
Total DebtN/A150K-
FUNDAMENTALS RATINGS
NTLA vs SONN: Fundamental Ratings
NTLA
SONN
OUTLOOK RATING
1..100
750
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
24
Undervalued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
8996
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SONN's Valuation (24) in the null industry is in the same range as NTLA (34) in the Biotechnology industry. This means that SONN’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as SONN (100) in the null industry. This means that NTLA’s stock grew similarly to SONN’s over the last 12 months.

NTLA's SMR Rating (96) in the Biotechnology industry is in the same range as SONN (100) in the null industry. This means that NTLA’s stock grew similarly to SONN’s over the last 12 months.

NTLA's Price Growth Rating (89) in the Biotechnology industry is in the same range as SONN (96) in the null industry. This means that NTLA’s stock grew similarly to SONN’s over the last 12 months.

SONN's P/E Growth Rating (96) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that SONN’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLASONN
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME27.370.91
+3.44%
GameStop Corp
AAPL228.223.10
+1.38%
Apple
SPY593.35-3.84
-0.64%
SPDR® S&P 500® ETF Trust
BTC.X87250.430000-3333.734400
-3.68%
Bitcoin cryptocurrency
TSLA311.18-19.06
-5.77%
Tesla

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with EDIT. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-6.15%
EDIT - NTLA
74%
Closely correlated
-6.42%
BEAM - NTLA
67%
Closely correlated
-4.33%
CRSP - NTLA
63%
Loosely correlated
-5.90%
PRME - NTLA
58%
Loosely correlated
-9.22%
DNLI - NTLA
56%
Loosely correlated
-3.98%
More

SONN and

Correlation & Price change

A.I.dvisor tells us that SONN and SNBIF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SONN and SNBIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SONN
1D Price
Change %
SONN100%
-2.60%
SNBIF - SONN
28%
Poorly correlated
N/A
NTLA - SONN
27%
Poorly correlated
-6.15%
PRME - SONN
27%
Poorly correlated
-9.22%
CHRS - SONN
26%
Poorly correlated
-0.78%
ABCL - SONN
26%
Poorly correlated
-5.48%
More